Comparisons of clinical features of HLA-DRB1*07 positive and negative vitiligo patients in Chinese Han population

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 11, 2011, Pages 1299-1303

  Hu, D Y ^a,b   Ren, Y Q ^a,b   Zhu, K J ^a,b   Lv, Y M ^a,b   Cheng, H ^a,b   Zhang, Z ^a,b   Li, Y ^a,b   He, S M ^a,b   Tang, J ^a,b   Liu, J L ^a,b   Lin, Y ^a,b   Sun, Y Y ^a,b   Zuo, X B ^b   Chen, G ^b   Sun, L D ^a,b   Yang, S ^a,b   Zhang, X J ^a,b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b State Key Laboratory Incubation Base of Dermatology   (China)

Author keywords

association; HLA DRB1*07; vitiligo

Indexed keywords

HLA DR ANTIGEN;

CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; VITILIGO;

ALLELES; CASE-CONTROL STUDIES; CHINA; ETHNIC GROUPS; HLA-DRB1 CHAINS; HUMANS; VITILIGO;

EID: 80054027137     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03971.x     Document Type: Review

References (27)

1. Hann SK, Nordlund JJ,. Vitiligo. Blackwell Science, Oxford, 2000.
2. Das SK, Majumder PP, Chakraborty R, et al. Studies on vitiligo. I. Epidemiological profile in Calcutta, India. Genet Epidemiol 1985; 2: 71-78. (Pubitemid 15101651)
3. Birlea SA, Fain PR, Spritz RA,. A Romanian population isolate with high frequency of vitiligo and associated autoimmune diseases. Arch Dermatol 2008; 144: 310-316. (Pubitemid 351439113)
4. Taieb A, Picardo M,. Clinical practice Vitiligo. N Engl J Med 2009; 360: 160-169.
5. Radtke MA, Schafer I, Gajur A, et al. Willingness-to-pay and quality of life in patients with vitiligo. Br J Dermatol 2009; 161: 134-139.
6. Zhang XJ, Liu JB, Gui JP, et al. Characteristics of genetic epidemiology and genetic models for vitiligo. J Am Acad Dermatol 2004; 51: 383-390.
7. Alkhateeb A, Fain PR, Thody A, et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 2003; 16: 208-214. (Pubitemid 36597056)
8. Dell'anna ML, Picardo M,. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res 2006; 19: 406-411. (Pubitemid 44326402)
9. Spritz RA,. The genetics of generalized vitiligo. Curr Dir Autoimmun 2008; 10: 244-257.
10. Laberge G, Mailloux CM, Gowan K, et al. Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo. Pigment Cell Res 2005; 18: 300-305. (Pubitemid 41032889)
11. Zhang Z, Xu SX, Zhang FY, et al. The analysis of genetics and associated autoimmune diseases in Chinese vitiligo patients. Arch Dermatol Res 2009; 301: 167-173.
12. Zhang XJ, Chen JJ, Liu JB,. The genetic concept of vitiligo. J Dermatol Sci 2005; 39: 137-146.
13. Xiao Y, Zhao YM, Song FJ,. Association of HLA-DRB1 alleles with generalized vitiligo in Chinese Hans in north China. Chinese J Dermatol 2000; 33: 5-7.
14. Wang J, Zhao YM, Wang Y, et al. Association of HLA class I and II alleles with generalized vitiligo in Chinese Hans in north China. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2007; 24: 221-223. (Pubitemid 46624804)
15. Wang XY, Jiang RH, Zhu MJ,. Association of HLA-DRB1 alleles with vitiligo and psoriasis vulgaris in Chinese Han people of Jilin region. Chinese J Immunol 2008; 28: 144-146.
16. Ren Y, Yang S, Xu S, et al. Genetic variation of promoter sequence modulates XBP1 expression and genetic risk for vitiligo. PLoS Genet 2009; 5: e1000523.
17. al Badri AM, Foulis AK, Todd PM, et al. Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo. J Pathol 1993; 169: 203-206. (Pubitemid 23063457)
18. Orozco-Topete R, Cordova-Lopez J, Yamamoto-Furusho JK, et al. HLA-DRB1*04 is associated with the genetic susceptibility to develop vitiligo in Mexican patients with autoimmune thyroid disease. J Am Acad Dermatol 2005; 52: 182-183. (Pubitemid 40038976)
19. Fain PR, Babu SR, Bennett DC, et al. HLA class II haplotype DRB1*04-DQB1*0301 contributes to risk of familial generalized vitiligo and early disease onset. Pigment Cell Res 2006; 19: 51-57.
20. Misri R, Khopkar U, Shankarkumar U, et al. Comparative case control study of clinical features and human leukocyte antigen susceptibility between familial and nonfamilial vitiligo. Indian J Dermatol Venereol Leprol 2009; 75: 583-587.
21. Dunston GM, Halder RM,. Vitiligo is associated with HLA-DR4 in black patients. A preliminary report. Arch Dermatol 1990; 126: 56-60. (Pubitemid 20040982)
22. Olerup O, Zetterquist H,. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225-235.
23. Zamani M, Spaepen M, Sghar SS, et al. Linkage and association of HLA class II genes with vitiligo in a Dutch population. Br J Dermatol 2001; 145: 90-94. (Pubitemid 32862792)
24. Tastan HB, Akar A, Orkunoglu FE, et al. Association of HLA class I antigens and HLA class II alleles with vitiligo in a Turkish population. Pigment Cell Res 2004; 17: 181-184. (Pubitemid 38419646)
25. Quan C, Ren YQ, Xiang LH, et al. Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat Genet 2010; 42: 614-618.
26. Le Poole IC, Van den Wijngaard RM, Westerhof W, et al. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 1996; 148: 1219-1228. (Pubitemid 26108257)
27. Van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C, et al. Local immune response in skin of generalized patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest 2000; 80: 1299-1309. (Pubitemid 30637070)